Gianpiero Fasola
Gianpiero Fasola
Direttore, Dipartimento di Oncologia, Presidio Ospedaliero Universitario, Azienda Sanitaria
Adresse e-mail validée de
Citée par
Citée par
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with …
LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, JR Hecht, ...
Journal of clinical oncology 32 (21), 2240-2247, 2014
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
TY Kim, GM Kim, M Martín, C Zielinski, M Ruíz-borrego, E Carrasco, ...
Journal of Clinical Oncology, 32-45, 2019
The role of UGT1A1* 28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
G Toffoli, E Cecchin, G Corona, A Russo, A Buonadonna, M D'Andrea, ...
Journal of Clinical Oncology 24 (19), 3061-3068, 2006
Clinical advances in the development of novel VEGFR2 inhibitors
C Fontanella, E Ongaro, S Bolzonello, M Guardascione, G Fasola, ...
Annals of translational medicine 2 (12), 2014
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B
F Menichetti, A Del Favero, P Martino, G Bucaneve, A Micozzi, ...
Annals of internal medicine 120 (11), 913-918, 1994
Measures of outcome in metastatic breast cancer: insights from a real-world scenario
M Bonotto, L Gerratana, E Poletto, P Driol, M Giangreco, S Russo, ...
The oncologist 19 (6), 608, 2014
Pattern of metastasis and outcome in patients with breast cancer
L Gerratana, V Fanotto, M Bonotto, S Bolzonello, AM Minisini, G Fasola, ...
Clinical & experimental metastasis 32 (2), 125-133, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921-1928, 2015
Expression of periostin in human breast cancer
F Puglisi, C Puppin, E Pegolo, C Andreetta, G Pascoletti, F D’Aurizio, ...
Journal of clinical pathology 61 (4), 494-498, 2008
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
Impact of third‐generation drugs on the activity of first‐line chemotherapy in advanced non‐small cell lung cancer: A meta‐analytical approach
F Grossi, M Aita, C Defferrari, F Rosetti, A Brianti, G Fasola, O Vinante, ...
The oncologist 14 (5), 497-510, 2009
Low‐dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos‐exposed population: baseline results of a prospective, nonrandomized feasibility …
G Fasola, O Belvedere, M Aita, T Zanin, A Follador, P Cassetti, S Meduri, ...
The oncologist 12 (10), 1215-1224, 2007
Body composition changes among female NCAA division 1 athletes across the competitive season and over a multiyear time frame
PR Stanforth, BN Crim, D Stanforth, MA Stults-Kolehmainen
The Journal of Strength & Conditioning Research 28 (2), 300-307, 2014
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients …
F Rivera, M Karthaus, JR Hecht, I Sevilla, F Forget, G Fasola, JL Canon, ...
International journal of colorectal disease 32 (8), 1179-1190, 2017
Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial
A Paccagnella, A Favaretto, F Oniga, F Barbieri, G Ceresoli, W Torri, ...
Lung Cancer 43 (1), 83-91, 2004
Drug waste minimisation and cost-containment in medical oncology: two-year results of a feasibility study
G Fasola, M Aita, L Marini, A Follador, M Tosolini, L Mattioni, M Mansutti, ...
BMC Health Services Research 8 (1), 1-8, 2008
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type …
LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, H Yu, ...
Journal of Clinical Oncology 31 (15_suppl), 3631-3631, 2013
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
L Fornaro, S Cereda, G Aprile, S Di Girolamo, D Santini, N Silvestris, ...
British journal of cancer 110 (9), 2165-2169, 2014
Drug waste minimization as an effective strategy of cost-containment in oncology
G Fasola, G Aprile, L Marini, A Follador, M Mansutti, M Miscoria
BMC health services research 14 (1), 1-7, 2014
Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study
G Leone, L Gugliotta, MG Mazzucconi, V De Stefano, MM Belmonte, ...
Thrombosis and haemostasis 69 (01), 012-015, 1993
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20